JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okumura, W.
Right arrow Articles by Kurabayashi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okumura, W.
Right arrow Articles by Kurabayashi, M.
Journal of Nuclear Medicine Vol. 45 No. 12 1989-1998
© 2004 by Society of Nuclear Medicine


Clinical Investigations

Usefulness of Fasting 18F-FDG PET in Identification of Cardiac Sarcoidosis

Wataru Okumura, MD1, Tsutomu Iwasaki, MD1, Takuji Toyama, MD1, Tatsuya Iso, MD1, Masashi Arai, MD1, Noboru Oriuchi, MD2, Keigo Endo, MD2, Tomoyuki Yokoyama, MD3, Tadashi Suzuki, MD4 and Masahiko Kurabayashi, MD1

1 Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan
2 Department of Diagnostic Radiology and Nuclear Medicine, Gunma University School of Medicine, Maebashi, Japan
3 Department of Laboratory Sciences, Gunma University School of Health Science, Maebashi, Japan
4 Fujioka General Hospital, Fujioka, Japan

Cardiac PET using 18F-FDG under fasting conditions (fasting 18F-FDG PET) is a promising technique for identification of cardiac sarcoidosis and assessment of disease activity. The aim of this study was to investigate the usefulness of fasting 18F-FDG PET in detecting inflammatory lesions of cardiac sarcoidosis from a pathophysiologic standpoint. Methods: Twenty-two patients with systemic sarcoidosis were classified into 2 groups of 11 each according to the presence or absence of sarcoid heart disease. Cardiac sarcoidosis was diagnosed according to the Japanese Ministry of Health and Welfare guidelines for diagnosing cardiac sarcoidosis with the exception of scintigraphic criteria. Nuclear cardiac imaging with fasting 18F-FDG PET, 99mTc-methoxyisobutylisonitrile (99mTc-MIBI) SPECT, and 67Ga scintigraphy were performed in all patients. PET and SPECT images were divided into 13 myocardial segments and the standardized uptake value (SUV) of 18F-FDG was calculated and defect scores (DS) for 99mTc-MIBI uptake were assessed for each segment. The total SUV (T-SUV) and total DS (TDS) were calculated as the sum of measurements for all 13 segments, and the diagnostic accuracy of fasting 18F-FDG PET was compared with that of the other nuclear imaging modalities. In addition, pathophysiologic relationships between inflammatory activity and myocardial damage were examined by segmental comparative study using the SUV and DS. Results: In patients with cardiac sarcoidosis, fasting 18F-FDG PET revealed a higher frequency of abnormal myocardial segments than 99mTc-MIBI SPECT (mean number of abnormal segments per patient: 6.6 ± 3.0 vs. 3.0 ± 3.2 [mean ± SD], P < 0.05). The sensitivity of fasting 18F-FDG PET in detecting cardiac sarcoidosis was 100%, significantly higher than that of 99mTc-MIBI SPECT (63.6%) or 67Ga scintigraphy (36.3%). The accuracy of fasting 18F-FDG PET was significantly higher than 67Ga scintigraphy. The T-SUV demonstrated a good linear correlation with serum angiotensin-converting enzyme levels (r = 0.83, P < 0.01), and the TDS showed a significant negative correlation with the left ventricular ejection fraction (r = –0.82, P < 0.01). In abnormal myocardial segments on the nuclear scan, the SUV showed a significant negative correlation with the DS (r = –0.63, P < 0.0001). Conclusion: This study suggests that fasting 18F-FDG PET can detect the early stage of cardiac sarcoidosis, in which fewer perfusion abnormalities and high inflammatory activity are noted, before advanced myocardial impairment.

Key Words: PET • 18F-FDG • fasting • cardiac sarcoidosis


Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8a-9a. [Full Text]  



This article has been cited by other articles:


Home page
ThoraxHome page
S Gyorik, L Ceriani, A Menafoglio, A Gallino, and R Wyttenbach
18F-FDG PET scan as follow-up tool for sarcoidosis with symptomatic cardiac conduction disturbances requiring a pacemaker
Thorax, June 1, 2007; 62(6): 560 - 560.
[Full Text] [PDF]


Home page
Eur Respir JHome page
C. Pandya, R. C. Brunken, P. Tchou, P. Schoenhagen, and D. A. Culver
Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques
Eur. Respir. J., February 1, 2007; 29(2): 418 - 422.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
Y. Nishiyama, Y. Yamamoto, K. Fukunaga, H. Takinami, Y. Iwado, K. Satoh, and M. Ohkawa
Comparative Evaluation of 18F-FDG PET and 67Ga Scintigraphy in Patients with Sarcoidosis
J. Nucl. Med., October 1, 2006; 47(10): 1571 - 1576.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A. R Doughan and B. R Williams
Cardiac sarcoidosis
Heart, February 1, 2006; 92(2): 282 - 288.
[Full Text] [PDF]


Home page
ChestHome page
M. A. Judson
Cardiac Sarcoidosis: There Is No Instant Replay
Chest, July 1, 2005; 128(1): 3 - 6.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.